GlobeNewswire

ConnectWise Launches Unite, Its Cloud Monitoring, Management and Billing Solution

Dela

IT Nation Europe keynote also reveals plans for an advanced security dashboard and growing the company's international footprint

LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- ConnectWise CEO Arnie Bellini told an audience of more than 350 at the company's annual IT Nation Europe conference in London that ConnectWise Unite is now available to technology teams across the globe. Unite is a cloud management solution that gives technology teams the ability to manage, monitor and bill a broad range of cloud-based solutions through a single pane of glass and in their own currency.

"Technology teams typically take advantage of a broad range of cloud solutions to meet their customers' unique needs. What we've done with ConnectWise Unite is give our partners the ability to access these disparate solutions from a single pane of glass and greatly simplify the complexity that comes from dealing with the growing number of solutions they use," Bellini said.

He explained that connecting the ecosystem seamlessly within Unite enables teams to more effectively and profitably deliver managed services to their clients, all while driving recurring revenues.

"We believe in a completely open ecosystem that offers technology teams choices in how they meet the unique needs of their customers, so we understand that teams need a tool to help them efficiently manage all their solutions. ConnectWise Unite does just this and returns to our partners the time they need to focus on providing their customers with great support and growing their businesses," Bellini said.

ConnectWise Unite integrations today include Amazon Web Services (AWS), Cisco Meraki, Cisco Spark, Cisco Stealthwatch Cloud, Cisco Umbrella, Microsoft Azure and Microsoft Office 365. Additional vendor solutions will be added based on partner needs and feedback.    

Advanced Security Dashboard

Bellini told audience members the company is preparing to launch the ConnectWise Advanced Security Dashboard, giving technology teams the ability to monitor a client's multiple security solutions from a single pane of glass. The Dashboard will incorporate endpoint security, network security, edge and application security, and testing and reporting.

He said ConnectWise has teamed once again with Cisco and will launch the Advanced Security Dashboard with many of Cisco's security solutions, including Cisco Advanced Malware Protection (AMP) for Endpoints, Cisco Advanced Security Appliances (ASA) and Cisco Next Generation Firewall (NGFW).

The ConnectWise Advanced Security Dashboard will be piloted in May for a select group of Cisco partners. Its launch is slated for September.  

International Growth

Bellini also touted the success ConnectWise is experiencing outside of the United States and told IT Nation Europe attendees about plans to beef up the company's presence in Australia and increase its presence in South Africa.

"Today, ConnectWise solutions are used by more 22,000 businesses in over 70 countries, and international revenue grew by 23 percent last year," he said. "The reception we've received outside the United States has been phenomenal, and we're doubling down on our commitment to ensuring technology teams across the globe have access to our award-winning solutions, stellar support team and amazing community."

Bellini reported that ConnectWise has experienced more than a 37 percent increase in the number of partners in Australia during the last two years, and that Australia and New Zealand all together accounted for almost 7.4 percent of ConnectWise's revenue in 2017. To ensure it can continue to meet the needs of its partners in this part of the world, ConnectWise opened a new office in Sydney, Australia, this month and is increasing the number of colleagues dedicated to the Australia and New Zealand market. The new office overlooks Darling Harbour and allows partners to receive on-site product training, education and face-to-face time with their account managers.

ConnectWise also is expanding its outreach to South Africa, where it already has a several dozen partners. The company is looking to double that number over the next year and has hired a team to support this effort, according to Gregg Lalle, Vice President of International Sales and Strategy for ConnectWise.

"Over the past several years, we stepped up our commitment to Europe and APAC, and we're proud of our impact there. When ConnectWise is successful, our partners have been successful, and that's what we strive for each and every day," said Lalle. "ConnectWise has wanted to expand into South Africa for some time now and we're thrilled to begin this push. We're applying the learnings from our previous international efforts to ensure we can increase the efficiency and productivity of companies based in South Africa as quickly as possible."

IT Nation Europe 2018, the largest European conference of its kind, provides three days of collaboration, networking and educational content for technology team members. To learn more about IT Nation Europe, visit the ConnectWise IT Nation Europe website

Follow ConnectWise  
LinkedIn
ConnectWise Blog
Twitter  
Facebook
YouTube

About ConnectWise
ConnectWise is a software company that connects technology teams to the solutions, services and resources necessary for success. Our award-winning business management platform automates the full lifecycle of technology service delivery, from sales and service to project tracking and back-office functions, for more than 22,000 in more than 70 countries. We believe in an open ecosystem, the power of choice and providing a single pane of glass view. With more than 35 years of experience, ConnectWise software solutions deliver the support companies want at each step of their business journey. For more information, visit www.ConnectWise.com.

Press Contacts
Elizabeth Bassler
EBassler@ConnectWise.com
Diane Rose for ConnectWise
diane@dkrcomms.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/930e4424-8f14-4595-908c-8613e31e572c




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ConnectWise via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum